Frontier Bio: Signs licensing agreement with GlaxoSmithKline; the company will receive a $40 million upfront payment and a $13 million milestone payment in the near term.

2026-02-23 09:03:52

Abstract generation in progress

Frontier Biotech announced that the company has entered into an exclusive licensing agreement with GlaxoSmithKline (GSK). Under the agreement, GSK will obtain exclusive rights worldwide to develop, manufacture, and commercialize two of Frontier Biotech’s small interfering RNA (siRNA) pipeline products. The company will receive a $40 million upfront payment and a $13 million near-term milestone payment, with the potential to earn up to $950 million in milestone payments and tiered royalties on global net sales. The company will be responsible for early development of the two pipeline products, while GSK will handle subsequent global clinical development, regulatory submissions, and commercialization activities. This deal is expected to improve the company’s cash flow and financial structure and accelerate the internationalization and value realization of its pipeline.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes